International Therapy Research

The great majority of the medications approved by the American and the European approval agencies FDA (Food and Drug Administration) and the EMA (European Medicines Agency) have been tested in large-scale therapeutic studies, provided with the approval seal of both major approval agencies and then released onto the market. Since cancer therapy is frequently difficult and yields disappointing results, access to information regarding new cancer medications is both important and indispensable. Furthermore, information about cancer medications currently being subjected to clinical studies is likewise useful since such information may later on play an important role for cancer therapies.

In the last 2 years, the following new cancer medications have been approved (list not exhaustive): Ipilimumab, an antagonist against CTLA-4 lymph cells, is extremely effective in treating malignant melanoma. Jevtana (Cabazitaxel®) and Abiraterone (Zytiga®) are two new substances for treating castration-resistant prostate carcinoma. One substance from the sea sponge, Eribulin (Halaven®), indicates effectiveness with heavily pre-treated metastasised breast cancer. Brentuximab Vedontin is an antibody coated with cytostatics that shows effectiveness when used on previously treated Hodgkin's lymphoma (PHL).

International Therapy Research

International therapy research, Centre for Cancer Medicine

Our consultation is based on the newest research results regarding effective oncological treatment.

We will gladly advise you and look forward to your contact request.